| Literature DB >> 33805717 |
Kelsey Moore1, Diana Fulmer1, Lilong Guo1, Natalie Koren1, Janiece Glover1, Reece Moore1, Cortney Gensemer1, Tyler Beck1, Jordan Morningstar1, Rebecca Stairley1, Russell A Norris1.
Abstract
Mitral valve prolapse (MVP) is a common form of valve disease and can lead to serious secondary complications. The recent identification of MVP causal mutations in primary cilia-related genes has prompted the investigation of cilia-mediated mechanisms of disease inception. Here, we investigate the role of platelet-derived growth factor receptor-alpha (PDGFRα), a receptor known to be present on the primary cilium, during valve development using genetically modified mice, biochemical assays, and high-resolution microscopy. While PDGFRα is expressed throughout the ciliated valve interstitium early in development, its expression becomes restricted on the valve endocardium by birth and through adulthood. Conditional ablation of Pdgfra with Nfatc1-enhancer Cre led to significantly enlarged and hypercellular anterior leaflets with disrupted endothelial adhesions, activated ERK1/2, and a dysregulated extracellular matrix. In vitro culture experiments confirmed a role in suppressing ERK1/2 activation while promoting AKT phosphorylation. These data suggest that PDGFRα functions to suppress mesenchymal transformation and disease phenotypes by stabilizing the valve endocardium through an AKT/ERK pathway.Entities:
Keywords: ERK1/2; PDGFRα; cardiac development; endothelial; mitral valve
Year: 2021 PMID: 33805717 PMCID: PMC7999759 DOI: 10.3390/jcdd8030028
Source DB: PubMed Journal: J Cardiovasc Dev Dis ISSN: 2308-3425